SCHEMBL5136876

SCHEMBL5136876

O=C(c1ccccc1-c1ccccc1)N(Cc1ccc2c(c1)OCO2)Cc1ccc2c(c1)OCO2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.59
HPGD P15428 3/20 0.59
MAPT P10636 1/20 0.59
GABRA1 P14867 1/20 0.58
GABRB2 P47870 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.51
TSHR P16473 3/20 0.51
MAPK1 P28482 2/20 0.51
USP2 O75604 2/20 0.51
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
KMT2A Q03164 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
TDP1 Q9NUW8 1/20 0.48
PTGES O14684 1/20 0.47
ALOX5 P09917 1/20 0.47
NR1H4 Q96RI1 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
MEN1 O00255 2/20 0.47
TAS2R14 Q9NYV8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134630 0.98 ALDH1A1 (0.62) ALDH1A1HPGDMAPTGABRA1GABRB2
SCHEMBL4766559 0.88 ALDH1A1 (0.55) ALDH1A1HPGDMAPTGABRA1GABRB2
SCHEMBL5134793 0.83 ALDH1A1 (0.55) ALDH1A1HPGDMAPTGABRA1GABRB2
SCHEMBL5136528 0.82 GABRA1 (0.46) ALDH1A1HPGDMAPTGABRA1GABRB2
SCHEMBL14099478 0.82 ALDH1A1 (0.64) ALDH1A1HPGDMAPTSMN1; SMN2TSHR
SCHEMBL4769015 0.79 ALDH1A1 (0.55) ALDH1A1HPGDMAPTSMN1; SMN2TSHR
SCHEMBL5137429 0.79 ALDH1A1 (0.44) ALDH1A1HPGDMAPTGABRA1GABRB2
SCHEMBL5353976 0.78 MEN1 (0.71) ALDH1A1SMN1; SMN2TSHRMAPK1KMT2A
SCHEMBL10107748 0.78 HPGD (0.66) ALDH1A1HPGDMAPTMAPK1LMNA
SCHEMBL4766609 0.75 ALDH1A1 (0.56) ALDH1A1HPGDMAPTSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed